Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
US Department of Justice
McKinsey
Baxter
Fuji
Cipla

Generated: July 17, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,532,955

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,532,955 protect, and when does it expire?

Patent 9,532,955 protects INVELTYS and is included in one NDA.

This patent has ten patent family members in seven countries.

Summary for Patent: 9,532,955
Title:Nanocrystals, compositions, and methods that aid particle transport in mucus
Abstract: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.
Inventor(s): Popov; Alexey (Waltham, MA), Enlow; Elizabeth M. (Waltham, MA), Bourassa; James (Somerville, MA), Gardner; Colin R. (Concord, MA), Chen; Hongming (Belmont, MA), Ensign; Laura M. (Towson, MD), Lai; Samuel K. (Carrboro, NC), Yu; Tao (Baltimore, MD), Hanes; Justin (Baltimore, MD), Yang; Ming (Towson, MD)
Assignee: Kala Pharmaceuticals, Inc. (Waltham, MA) The Johns Hopkins University (Baltimore, MD)
Application Number:15/187,552
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 9,532,955
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Delivery;

Drugs Protected by US Patent 9,532,955

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Kala Pharms Inc INVELTYS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210565-001 Aug 22, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Federal Trade Commission
UBS
Chubb
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.